: Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.

Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022 / Fabiani, Massimo; Mateo-Urdiales, Alberto; Sacco, Chiara; Fotakis, Emmanouil Alexandros; Rota, Maria Cristina; Petrone, Daniele; Bressi, Marco; Del Manso, Martina; Siddu, Andrea; Fedele, Giorgio; Stefanelli, Paola; Bella, Antonino; Riccardo, Flavia; Palamara, Anna Teresa; Rezza, Giovanni; Brusaferro, Silvio; Pezzotti, Patrizio. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 28:8(2023), pp. 1-7. [10.2807/1560-7917.ES.2023.28.8.2300105]

Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022

Petrone, Daniele;
2023

Abstract

: Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.
2023
COVID-19; Italy; SARS-CoV-2; bivalent mRNA vaccines; effectiveness; elderly population
01 Pubblicazione su rivista::01a Articolo in rivista
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022 / Fabiani, Massimo; Mateo-Urdiales, Alberto; Sacco, Chiara; Fotakis, Emmanouil Alexandros; Rota, Maria Cristina; Petrone, Daniele; Bressi, Marco; Del Manso, Martina; Siddu, Andrea; Fedele, Giorgio; Stefanelli, Paola; Bella, Antonino; Riccardo, Flavia; Palamara, Anna Teresa; Rezza, Giovanni; Brusaferro, Silvio; Pezzotti, Patrizio. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 28:8(2023), pp. 1-7. [10.2807/1560-7917.ES.2023.28.8.2300105]
File allegati a questo prodotto
File Dimensione Formato  
Fabiani_Protection-against-severe-COVID-19_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 226.82 kB
Formato Adobe PDF
226.82 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1673368
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact